World's Best Scientists 2026 revealed!
International Journal of Oncology
H-index 26

International Journal of Oncology

1019-6439

Published by: Spandidos Publications

https://www.spandidos-publications.com/ijo/editorial

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 1215 60 70 20

Additional Metrics

Number of Best Scientists*: 195
Documents by Best Scientists*: 182
Top 100 Ranked Scientists*: 2
SCIMAGO H-index: 142
SCIMAGO SJR: 1.226
Impact Factor: 4.9

Overview

Top Research Topics at International Journal of Oncology?

The main points discussed in the journal deals with Cancer research, Cell cycle, Oncogene, Cancer and Cell. While the primary focus in the journal is Cancer research, it also dissects topics surrounding Protein kinase B and PI3K/AKT/mTOR pathway as a whole. The study of Molecular biology and how it intertwines with concepts under Gene were explored in the presented Cell cycle research.

The research on Oncogene featured in it combines topics in other fields like Immunohistochemistry, Molecular medicine, Downregulation and upregulation, microRNA and Regulation of gene expression. Cancer research discussed connects with the study of Pathology. Pathology research is the primary subject tackled in the journal with a focus on Carcinoma.

It features Cell research that overlaps with concepts in Transfection. The journal addresses concerns in Apoptosis which are intertwined with other disciplines, such as Cisplatin, In vivo and Pharmacology. It facilitates discussions on Internal medicine that incorporate concepts from other fields like Gastroenterology, Endocrinology and Oncology.

  • Cancer research (56.39%)
  • Cell cycle (45.89%)
  • Oncogene (36.77%)

What are the most cited papers published in the journal?

  • A NEW FLUOROMETRIC ASSAY FOR CYTOTOXICITY MEASUREMENTS IN-VITRO (482 citations)
  • The anti-malarial artesunate is also active against cancer (477 citations)
  • Apigenin and cancer chemoprevention: Progress, potential and promise (Review) (404 citations)

Research areas of the most cited articles at International Journal of Oncology:

The journal articles are mainly concerned with subjects like Cancer research, Cancer, Cell cycle, Oncogene and Pathology. The journal papers explore topics in Cancer research which can be helpful for research in disciplines like Endocrinology, Cancer cell, Apoptosis, Carcinogenesis and Immunology. The most cited articles deal with Cell cycle in conjunction with Cell growth and similar fields in PI3K/AKT/mTOR pathway.

What topics the last edition of the journal is best known for?

  • Gene
  • Cancer
  • Internal medicine

The previous edition focused in particular on these issues:

The primary areas of discussion in International Journal of Oncology are Cancer research, Cell cycle, Oncogene, Cell and Cancer. The studies on Cancer research discussed can also contribute to research in the domains of Carcinogenesis, Protein kinase B, PI3K/AKT/mTOR pathway and Metastasis. The presentations focused mostly on Cell cycle in an attempt to further explore topics in Apoptosis.

While Oncogene is the key highlight in it, it also covered some subjects on microRNA and Competing endogenous RNA and Osteosarcoma. In the journal, Cell culture, Gene silencing, Flow cytometry and Small interfering RNA are investigated in conjunction with one another to address concerns in Cell research. Cancer research presented falls under the umbrella topic of Internal medicine.

The most cited articles from the last journal are:

  • Current molecular and clinical insights into uveal melanoma (Review) (7 citations)
  • Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines (6 citations)
  • Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review). (5 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in International Journal of Oncology (based on the number of publications) are:

  • Masaru Katoh (97 papers) absent at the last edition,
  • Masaki Mori (81 papers) absent at the last edition,
  • Yuichiro Doki (48 papers) absent at the last edition,
  • Demetrios A. Spandidos (45 papers) published 1 paper at the last edition, 6 less than at the previous edition,
  • Masuko Katoh (44 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in International Journal of Oncology (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (141 papers) absent at the last edition,
  • Osaka University (122 papers) absent at the last edition,
  • Chiba University (118 papers) absent at the last edition,
  • Kyushu University (115 papers) absent at the last edition,
  • Shanghai Jiao Tong University (111 papers) published 1 paper at the last edition, 7 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 6.06% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 4.30% were posted by at least one author from the top 10 institutions publishing in the journal. Another 10.75% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 26.88% of all publications and 58.06% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Prospects and Requirements for Oncology Nurses in Delaware

Oncology nurses have an essential role in the field of healthcare and cancer research. These professionals work hand-in-hand with patients, providing stable care to individuals diagnosed with cancer. If you are an oncology nurse considering advancing your career or are a professional in the field of oncology interested in shifting to a more patient-centered role in Delaware, understanding the delaware nursing license requirements and nursing license cost is pivotal.

Most states, including Delaware, require a professional nursing license to perform specific roles and operations in the medical field. The licensing often involves an examination and can incur a series of costs. Furthermore, specialized areas such as oncology might necessitate further certification or education. Therefore, those considering a career in the field or the state of Delaware should familiarize themselves with these processes.

Fulfilling all these requirements can, in turn, open an array of rewarding career avenues in the oncology sector. This, coupled with the continuous strides in cancer research, provides a fulfilling landscape for professionals in the field. For a comprehensive look, potential candidates should refer to the official state website or professional nursing bodies for the most current and accurate information.

Top Publications

  • Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.

    Shuhai Chen;Yuji Morine;Kazunori Tokuda;Shinichiro Yamada

    (2021)
    100 Citations
  • Cutaneous melanoma and the immunotherapy revolution (Review)

    Giulia C. Leonardi;Saverio Candido;Luca Falzone;Demetrios A. Spandidos

    (2020)
    85 Citations
  • Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care (Review)

    Eleftherios Trivizakis;Georgios Z. Papadakis;Ioannis Souglakos;Nikolaos Papanikolaou

    (2020)
    78 Citations
  • Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.

    Yoshihito Yamakoshi;Hiroaki Tanaka;Chie Sakimura;Sota Deguchi

    (2020)
    66 Citations
  • Immune-checkpoint inhibitors from cancer to COVID­19: A promising avenue for the treatment of patients with COVID­19 (Review).

    Silvia Vivarelli;Luca Falzone;Francesco Torino;Giuseppa Scandurra

    (2020)
    50 Citations
  • Human‑made electromagnetic fields: Ion forced‑oscillation and voltage‑gated ion channel dysfunction, oxidative stress and DNA damage (Review)

    Dimitris J Panagopoulos;Andreas Karabarbounis;Igor Yakymenko;George P Chrousos

    (2021)
    47 Citations
  • Pan­cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS­CoV­2 infection leading to COVID-19.

    Periklis Katopodis;Vladimir Anikin;Harpal S. Randeva;Demetrios A. Spandidos

    (2020)
    46 Citations
  • Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?

    (2022)
    41 Citations
  • CYP11A1-derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas

    (2022)
    41 Citations
  • Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer.

    Masako Nakamura;Atsushi Takano;Phung Manh Thang;Bayarbat Tsevegjav

    (2020)
    38 Citations

Related Online Degrees & Career Pathways

For those interested in expanding their healthcare expertise or exploring allied fields, several online degree options offer flexibility and affordability. Programs like dnp online programs cheap provide advanced practice registered nurses the opportunity to advance their careers while managing costs.

Nurses aiming to elevate their qualifications may consider affordable online RN to BSN programs, with research highlighting the average cost of rn to bsn programs designed to suit various budgets. Some of these programs also offer the benefit of being accessible without traditional entrance exams.

For those who prefer less rigorous admission barriers, there are nursing programs that don’t require TEAS, making it easier to start or continue a nursing education without the added pressure of standardized tests.

Additionally, professionals interested in healthcare management can explore the cost of MHA degree programs, which provide essential skills for leadership roles in healthcare administration, often available online for flexibility.

Best Scientists Contributing to This Journal

Recently Published Articles